Download
ServicesSpeciesAdministration RoutesSamplingSurgical ModelsFeature Platforms
Medicilon has significant experience in the research and development of inhaled drugs. Before testing, we will conduct a preliminary exploration of particle size, concentration, and aerosol generation.
In terms of species selection, Medicilon has mice, rats, rabbits (Dutch bunted rabbit, New Zealand white rabbit), monkeys, dogs, miniature pigs and other animals to carry out ophthalmic drug substitution research.
The Medicilon Liver Biopsy Guided By B-ultrasound In Cynomolgus Monkeys Platform can avoid the large blood vessels and gallbladder and has the advantages of less trauma, safe and simple puncture operation, accurate positioning, and better postoperative recovery.
The pharmacokinetc research studies sample in vivo behaviors, such as distribution, proliferation and survival time. We also track transgenic product expressed and secreted outside of the immune cells to assess its local and/or systemic exposure characteristics.
We can further characterise PROTAC molecules by using our integrated preclinical services including PK/PD studies, pharmacological analysis, pharmacokinetic studies, and safety evaluation.
| Determinand | Description | Typical analysis method |
|---|---|---|
| Conjugated Antibody | Antibody conjugated to at least one drug | LBA |
| Total Antibody | Fully conjugated, partially conjugated and unconjugated antibodies | LBA |
| Small Molecules | Free or diluted drug micromolecules and their metabolites | LC-MS/MS |
| ADA | Antibodies that can specifically bind ADC molecules and their partial structures | LBA |
Evaluation performance
SoftwareService Cases
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
Learn more about "In Vivo Pharmacokinetic Assays"FAQThe Caco-2 cell line is a human colon adenocarcinoma epithelial cell that can differentiate itself into a monolayer similar to a mature human small intestinal epithelial cell.
(1) Complete absorption (preferably passive absorption), bioavailability > 50% and minimal variation;
(2) AUC is proportional to dose, and there is a clear PK/PD correlation;
(3) Quickly reaches the target organ and do not accumulate outside it;
(4) PPB < 90%, unaffected by concentration and time;
(5) Plasma clearance CL < 30% of Qh, cleared through various routes;
(6) Age, race, gender, disease state, etc. have little effect on CL; low quantity of metabolites and no production of reactive metabolites;
(7) metabolite quantity is low and no reactive metabolites are produced;
(8) Does not inhibit or induce major drug metabolizing enzymes and transporters, and is not affected by food;
(9) T1/2>6hr in human body, reducing the dosing frequency and improving compliance.
(1) The liver is the main organ of drug metabolism, but not the only way of drug elimination. There is also renal elimination, etc.
(2) The drug is unstable in the blood, and the clearance of the drug does not have a hepatic effect.
(3) In some cases, when the drug concentration in red blood cells is much higher than that in plasma, the calculation of proper clearance cannot be approximated by the drug concentration in plasma.
(4) In individual cases, metabolism or uptake by the lungs occupies a significant role.
(1) Dose deviation due to administration error.
(2) Nonlinear pharmacokinetics (Nonlinear PK).
(3) High bioavailability and individual variability in the DMPK properties of the drug, with IV and PO, given to different groups of animals.
(4) Overestimation of PO AUC or underestimation of IV AUC due to unreasonable sampling points.
(5) IV samples were left for extended periods, and compounds were unstable in plasma.
(6) When administered as a racemate, the faster-clearing enantiomer is converted to the slower-clearing enantiomer in the GI tract.
Relevant laboratories
Relevant articles
marketing@medicilon.com
